Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.25
MSLI's Cash to Debt is ranked lower than
85% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. MSLI: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
MSLI' s 10-Year Cash to Debt Range
Min: 0.03  Med: 13.30 Max: No Debt
Current: 0.25
Equity to Asset 0.59
MSLI's Equity to Asset is ranked lower than
55% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MSLI: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
MSLI' s 10-Year Equity to Asset Range
Min: 0.18  Med: 0.65 Max: 0.94
Current: 0.59
0.18
0.94
F-Score: 5
Z-Score: 2.27
M-Score: -2.13
WACC vs ROIC
17.82%
5.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 7.53
MSLI's Operating margin (%) is ranked higher than
50% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. MSLI: 7.53 )
Ranked among companies with meaningful Operating margin (%) only.
MSLI' s 10-Year Operating margin (%) Range
Min: -1112.12  Med: -0.41 Max: 19.4
Current: 7.53
-1112.12
19.4
Net-margin (%) -7.59
MSLI's Net-margin (%) is ranked lower than
79% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. MSLI: -7.59 )
Ranked among companies with meaningful Net-margin (%) only.
MSLI' s 10-Year Net-margin (%) Range
Min: -1787.71  Med: -3.50 Max: 30.37
Current: -7.59
-1787.71
30.37
ROE (%) -2.75
MSLI's ROE (%) is ranked lower than
73% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. MSLI: -2.75 )
Ranked among companies with meaningful ROE (%) only.
MSLI' s 10-Year ROE (%) Range
Min: -150.16  Med: -6.96 Max: 22.94
Current: -2.75
-150.16
22.94
ROA (%) -1.69
MSLI's ROA (%) is ranked lower than
71% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. MSLI: -1.69 )
Ranked among companies with meaningful ROA (%) only.
MSLI' s 10-Year ROA (%) Range
Min: -65.49  Med: -3.46 Max: 8.84
Current: -1.69
-65.49
8.84
ROC (Joel Greenblatt) (%) 81.54
MSLI's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. MSLI: 81.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MSLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -627.84  Med: -14.27 Max: 92.73
Current: 81.54
-627.84
92.73
EPS Growth (3Y)(%) -43.90
MSLI's EPS Growth (3Y)(%) is ranked lower than
91% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MSLI: -43.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MSLI' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.2  Med: -2.90 Max: 108
Current: -43.9
-54.2
108
» MSLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MSLI Guru Trades in Q2 2014

Jim Simons 587,900 sh (+52.58%)
» More
Q3 2014

MSLI Guru Trades in Q3 2014

Jim Simons 358,400 sh (-39.04%)
» More
Q4 2014

MSLI Guru Trades in Q4 2014

Jim Simons 328,700 sh (-8.29%)
» More
Q1 2015

MSLI Guru Trades in Q1 2015

Jim Simons 436,200 sh (+32.70%)
» More
» Details

Insider Trades

Latest Guru Trades with MSLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 24.10
MSLI's Forward P/E is ranked lower than
57% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. MSLI: 24.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.35
MSLI's P/B is ranked higher than
65% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MSLI: 2.35 )
Ranked among companies with meaningful P/B only.
MSLI' s 10-Year P/B Range
Min: 0.29  Med: 0.76 Max: 2.77
Current: 2.35
0.29
2.77
P/S 5.93
MSLI's P/S is ranked lower than
68% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. MSLI: 5.93 )
Ranked among companies with meaningful P/S only.
MSLI' s 10-Year P/S Range
Min: 0.9  Med: 3.57 Max: 52.5
Current: 5.93
0.9
52.5
PFCF 20.94
MSLI's PFCF is ranked higher than
75% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. MSLI: 20.94 )
Ranked among companies with meaningful PFCF only.
MSLI' s 10-Year PFCF Range
Min: 1.3  Med: 6.33 Max: 175
Current: 20.94
1.3
175
POCF 12.24
MSLI's POCF is ranked higher than
84% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. MSLI: 12.24 )
Ranked among companies with meaningful POCF only.
MSLI' s 10-Year POCF Range
Min: 1.25  Med: 5.94 Max: 125
Current: 12.24
1.25
125
EV-to-EBIT 145.08
MSLI's EV-to-EBIT is ranked lower than
90% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. MSLI: 145.08 )
Ranked among companies with meaningful EV-to-EBIT only.
MSLI' s 10-Year EV-to-EBIT Range
Min: -628.5  Med: -1.20 Max: 125.6
Current: 145.08
-628.5
125.6
Current Ratio 1.33
MSLI's Current Ratio is ranked lower than
77% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MSLI: 1.33 )
Ranked among companies with meaningful Current Ratio only.
MSLI' s 10-Year Current Ratio Range
Min: 0.38  Med: 2.59 Max: 14.42
Current: 1.33
0.38
14.42
Quick Ratio 1.20
MSLI's Quick Ratio is ranked lower than
67% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. MSLI: 1.20 )
Ranked among companies with meaningful Quick Ratio only.
MSLI' s 10-Year Quick Ratio Range
Min: 0.31  Med: 2.53 Max: 14.42
Current: 1.2
0.31
14.42
Days Inventory 199.71
MSLI's Days Inventory is ranked lower than
82% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. MSLI: 199.71 )
Ranked among companies with meaningful Days Inventory only.
MSLI' s 10-Year Days Inventory Range
Min: 153.34  Med: 354.12 Max: 29863.64
Current: 199.71
153.34
29863.64
Days Sales Outstanding 84.23
MSLI's Days Sales Outstanding is ranked lower than
59% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. MSLI: 84.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
MSLI' s 10-Year Days Sales Outstanding Range
Min: 3.61  Med: 175.86 Max: 767.37
Current: 84.23
3.61
767.37

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.74
MSLI's Price/Projected FCF is ranked higher than
65% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. MSLI: 1.74 )
Ranked among companies with meaningful Price/Projected FCF only.
MSLI' s 10-Year Price/Projected FCF Range
Min: 0.15  Med: 0.78 Max: 3.52
Current: 1.74
0.15
3.52
Price/Median PS Value 1.83
MSLI's Price/Median PS Value is ranked lower than
66% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MSLI: 1.83 )
Ranked among companies with meaningful Price/Median PS Value only.
MSLI' s 10-Year Price/Median PS Value Range
Min: 0.02  Med: 0.59 Max: 14.29
Current: 1.83
0.02
14.29
Earnings Yield (Greenblatt) (%) 0.73
MSLI's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MSLI: 0.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MSLI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.75  Med: 59.70 Max: 4864.8
Current: 0.73
0.75
4864.8

Analyst Estimate

Sep15 Sep16 Sep17 Sep18
EPS($) 0.05 0.09 0.07 0.03
EPS without NRI($) 0.05 0.09 0.07 0.03

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:MSL.Canada,
Merus Labs International Inc is incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory. Competition also comes from generic companies, which develop and commercialize formulations that are identical to marketed brands.
» More Articles for MSLI

Headlines

Articles On GuruFocus.com
Update on Merus Labs International, Athabasca Minerals Inc, Enghouse Systems Limited, WiLAN Inc. Jun 22 2015 
Merus Labs International: A Pharma Stock With Growth Potential Mar 30 2015 
Merus Labs International Inc. Announces Normal Course Issuer Bid Nov 17 2014 

More From Other Websites
Merus Labs Provides an Update on German Reimbursement Review Jun 09 2015
Merus Labs Provides an Update on German Reimbursement Review Jun 03 2015
Merus Labs Provides an Update on German Reimbursement Review Jun 03 2015
MERUS LABS INTERNATIONAL INC. ANNOUNCES CLOSING OF EXERCISE OF OVER-ALLOTMENT OPTION Jun 02 2015
May 26, 2015 Merus Labs Appoints Frank Rotmann VP & Head of European Operations Jun 02 2015
May 28, 2015 Merus Labs To Present at Jefferies 2015 Healthcare Conference in New York Jun 02 2015
Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option Jun 01 2015
Coverage initiated on Merus Labs by TD Securities May 29 2015
Merus Labs to Present at Jefferies 2015 Healthcare Conference in New York May 28 2015
Merus Labs to Present at Jefferies 2015 Healthcare Conference in New York May 28 2015
May 22, 2015 Merus Labs Acquires Specialty Product Rights in Multiple Countries May 28 2015
Merus Labs Appoints Frank Rotmann VP & Head of European Operations May 26 2015
Merus Labs Appoints Frank Rotmann VP & Head of European Operations May 26 2015
May 13, 2015 Merus Labs Reports Strong Q2 2015 Results May 25 2015
Merus Labs Acquires Specialty Product Rights in Multiple Countries May 22 2015
Merus Labs Acquires Specialty Product Rights in Multiple Countries May 22 2015
Merus Labs International Inc. Announces Closing of $60.0 Million Bought Deal Financing May 15 2015
Merus Labs Reports Strong Q2 2015 Results May 13 2015
Merus Labs Reports Strong Q2 2015 Results May 13 2015
Merus Labs to Host Q2 Results Conference Call May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK